Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Mariella G. Filbin, MD, PhD

  • Research Co-Director, Pediatric Neuro-Oncology Program
  • Physician
  • Assistant Professor of Pediatrics, Harvard Medical School

Appointment Phone

  • 888-733-4662 (New Pediatric Patients)
  • 617-632-3270 (Established Pediatric Patients)

General

Treatment Centers

Discipline

Clinical Interests

DIPG, Ependymomas, ETMR, High-grade gliomas, Pediatric brain tumors, Translational neuro-oncology

Location

Background

Board Certifications

  • Pediatric Hematology/Oncology, 2019
  • Pediatrics, 2013

Fellowship

  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Pediatric Hematology/Oncology, 2017

Residency

  • Boston Children's Hospital, Pediatrics, 2013

Medical School

  • Medical University of Graz, Austria, 2004

Biography

Dr. Mariella Filbin earned her MD and PhD in biochemistry and molecular biology from the Medical University of Graz, Austria. After a pediatric residency at Boston Children’s Hospital, she completed a fellowship in pediatric hematology/oncology at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. She joined the faculty at Dana-Farber/Boston Children's as a pediatric neuro-oncologist in July 2017. In addition to her role in the treatment of patients with brain tumors, her research focuses on establishing cellular networks of tumor dependencies in pediatric brain tumors with the goal of finding new targeted therapies. Current areas of emphasis are: (1) utilizing single-cell transcriptomics to determine the tumor architecture and heterogeneity in pediatric brain tumors and (2) exploring the downstream effects of epigenetic driver mutations and their potential therapeutic applications in DIPG and high-grade gliomas.